Foliglurax - Lundbeck

Drug Profile

Foliglurax - Lundbeck

Alternative Names: Foliglurax; PXT-2331; PXT002331

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Domain Therapeutics
  • Developer Prexton Therapeutics
  • Class Antiparkinsonians; Morpholines; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 31 Mar 2018 Lundbeck acquires foliglurax from Prexton Therapeutics
  • 28 Mar 2018 Chemical structure information added
  • 20 Mar 2018 Prexton Therapeutics withdraws the phase II ATTUNED trial prior to enrolment due to business reasons in Parkinson's disease (Treatment-experienced) (PO) (NCT03331848)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top